Project Sales Sample Clauses

Project Sales. Without duplication of any prepayment for a Disposition in connection with a Permitted Tax Equity Arrangement for which a prepayment is made pursuant to Section 2.04(b)(ii): (A) if the Borrower directly or indirectly Disposes of any property in any Project Sale or any Partial Project Sale (in each case, including all or any portion of the Equity Interests owned, directly or indirectly, by the Borrower in any Subsidiary of the Borrower to a Tax Equity Investor, to the extent not covered by Section 2.04(b)(ii) below), the Borrower shall prepay, or cause to be prepaid, within five (5) Business Days of such Disposition, an aggregate principal amount of Loans (together with any amounts required pursuant to Section 2.04(a)(ii)) necessary to comply with the Maximum Loan Amount as of the date of such prepayment, calculated and determined giving effect to such Disposition; and (B) if the Borrower directly or indirectly Disposes of any property in any Project Sale or any Partial Project Sale (in each case, including all or any portion of the Equity Interests owned, directly or indirectly, by the Borrower in any Subsidiary of the Borrower to a Tax Equity Investor, to the extent not covered by Section 2.04(b)(ii) below), and as a result thereof one or more of the Concentration Limits are not satisfied and such failure to satisfy such Concentration Limit is not cured by the earlier of (i) the date that is the last Business Day of the full Fiscal Quarter following the Fiscal Quarter in which such Disposition occurred and (ii) the Maturity Date, the Borrower shall prepay, or cause to be prepaid, an amount equal to the aggregate principal amount of Loans (together with any amounts required pursuant to Section 2.04(a)(ii)) necessary to cause the Borrower to be in compliance with the Concentration Limits as of the date of such prepayment, as determined with reference to the Maximum Loan Amount as of the date of such prepayment, calculated and determined without giving effect to the Borrower’s Net Cash Flows that are not then in compliance with the Concentration Limits.
View SourceView Similar (3)
Project Sales. There are no outstanding indemnification claims or payments, purchase price payments or purchase price adjustments (including earn-outs and similar post-closing adjustments) to be made to or by any Person with respect to any of the Project Sales for which Seller Parent, Seller, the Company or Company Subsidiary is liable. There are no indemnification claims or indemnification payments, purchase price payments or purchase price adjustments (including earn-outs and similar post-closing adjustments) that will in the future be required to be made to or by any Person with respect to any of the Project Sales for which Seller Parent, Seller, the Company or Company Subsidiary is or will be liable.
View Source

Related to Project Sales

  • Direct Sales The Manager will advise you promptly, on the Offering Date, as to the Securities purchased by you pursuant to the Underwriting Agreement that you will retain for direct sale. At any time prior to the termination of the applicable AAU, any such Securities that are held by the Manager for sale but not sold may, on your request and at the Manager’s discretion, be released to you for direct sale, and Securities so released to you will no longer be deemed held for sale by the Manager. You may allow, and Dealers may reallow, a discount on sales to Dealers in an amount not in excess of the Reallowance set forth in the applicable AAU. You may not purchase Securities from, or sell Securities to, any other Underwriter or Dealer at any discount or concession other than the Reallowance, except with the prior consent of the Manager.

  • PROJECT SERVICES Landlord shall furnish services as follows:

  • Projects There shall be a thirty (30) km free zone around the projects excluding the Metro Vancouver Area. For local residents, kilometers shall be paid from the boundary of the free zone around the project. Workers employed by any contractor within an identified free zone who resides outside of that same free zone will be paid according to the Kilometer Chart from the project to their residence less thirty

  • Annual Work Plans and Budgets The Recipient shall furnish to the Association as soon as available, but in any case not later than September 1 of each year, the annual work plan and budget for the Project for each subsequent year of Project implementation, of such scope and detail as the Association shall have reasonably requested, except for the annual work plan and budget for the Project for the first year of Project implementation, which shall be furnished no later than one (1) month after the Effective Date.

  • Product Sales Subject to Sections 10.3(c) and 10.3(d), Licensee agrees that it will not sell, offer for sale, or assist third parties (including Affiliates) in selling Product except for the sale and offer for sale of (A) TAF Product, TAF Combination Product, TDF Product and TDF Combination Product for use in the Field and in the countries of the TDF-TAF Territory, (B) COBI Product and COBI Combination Product for use in the Field and in the countries of the COBI Territory, and (C) EVG Product, EVG Combination Product and Quad Product for use in the Field and in the countries of the EVG-Quad Territory.‌ (i) Licensee agrees that during the period in which the Patents are valid and enforceable (on a Product-by-Product basis) it will prohibit its Distributors from selling Product (A) to any other wholesaler or distributor, (B) outside the Territory for which Licensee is licensed for sale of such Product pursuant to Section 2.2, or (C) for any purpose outside the Field. (ii) Licensee agrees that it will not administer the TAF Quad to humans, or sell the TAF Quad until Gilead has obtained marketing approval for the TAF Quad from the FDA. Licensee agrees that it will not administer EVG to humans, or sell Products containing EVG until Gilead has obtained marketing approval for an EVG Product from the FDA. Licensee agrees that it will not administer COBI to humans, or sell Products containing COBI until Gilead has obtained marketing approval for a COBI Product from the FDA. Licensee agrees that it will not administer TAF to humans, or sell Products containing TAF until Gilead has obtained marketing approval for a TAF Product from the FDA. If Gilead obtains marketing approval from the FDA for any Quad Product or a Combination Product containing TAF, COBI or EVG (“Approved Combination Product”) prior to obtaining marketing approval for a TAF Product, EVG Product or COBI Product from the FDA, then Licensee will be allowed to administer such Quad Product or such Approved Combination Product to humans, and sell such Quad Product or such Approved Combination Product from and after the date of such marketing approval from the FDA, but will not (A) administer to humans or sell Combination Products containing EVG other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for an EVG Product, or (B) administer to humans or sell Combination Products containing COBI other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a COBI Product or (C) administer to humans or sell Combination Products containing TAF other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a TAF Product.